Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Increases By 113.3%

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) saw a large increase in short interest in June. As of June 30th, there was short interest totaling 441,157 shares, an increase of 113.3% from the June 15th total of 206,873 shares. Approximately 7.8% of the company’s shares are short sold. Based on an average daily volume of 302,873 shares, the short-interest ratio is currently 1.5 days.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded shares of Armata Pharmaceuticals to a “hold” rating in a report on Monday, May 18th. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $15.00.

Institutional Investors Weigh In On Armata Pharmaceuticals

Several hedge funds have recently modified their holdings of ARMP. Madison Asset Management LLC purchased a new stake in Armata Pharmaceuticals in the first quarter valued at approximately $21,583,000. 683 Capital Management LLC purchased a new position in Armata Pharmaceuticals during the fourth quarter worth approximately $878,000. Sei Investments Co. acquired a new position in shares of Armata Pharmaceuticals in the 1st quarter valued at $760,000. Goldman Sachs Group Inc. acquired a new position in shares of Armata Pharmaceuticals in the 4th quarter valued at $284,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in shares of Armata Pharmaceuticals during the 4th quarter valued at $177,000. 3.57% of the stock is owned by institutional investors and hedge funds.

Armata Pharmaceuticals Stock Down 5.8%

Shares of NYSEAMERICAN:ARMP opened at $3.76 on Friday. The company has a market cap of $138.03 million, a P/E ratio of -0.48 and a beta of 1.26. Armata Pharmaceuticals has a 52 week low of $2.32 and a 52 week high of $16.34. The business has a fifty day simple moving average of $7.01 and a 200-day simple moving average of $8.36.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last released its earnings results on Wednesday, May 13th. The company reported ($3.16) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($2.78). The company had revenue of $0.79 million during the quarter, compared to analysts’ expectations of $0.74 million. Sell-side analysts expect that Armata Pharmaceuticals will post -1.88 earnings per share for the current fiscal year.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.